104 related articles for article (PubMed ID: 30033225)
1. Clinical and genomic features of a subtype of prostate cancer.
Venkatesan P
Lancet Oncol; 2018 Aug; 19(8):e394. PubMed ID: 30033225
[No Abstract] [Full Text] [Related]
2. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
Puca L; Vlachostergios PJ; Beltran H
Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29844220
[TBL] [Abstract][Full Text] [Related]
3. [Aggressive variants of castration resistant prostate cancer (CRPC): neuroendocrine prostate cancer.].
Quicios-Dorado C; Bolufer-Moragues E; Gomis-Goti C; Cabello-Benavente R; Cannata-Ortiz PJ; González-Enguita C
Arch Esp Urol; 2018 Sep; 71(8):721-734. PubMed ID: 30319132
[TBL] [Abstract][Full Text] [Related]
4. miR-663 induces castration-resistant prostate cancer transformation and predicts clinical recurrence.
Jiao L; Deng Z; Xu C; Yu Y; Li Y; Yang C; Chen J; Liu Z; Huang G; Li LC; Sun Y
J Cell Physiol; 2014 Jul; 229(7):834-44. PubMed ID: 24243035
[TBL] [Abstract][Full Text] [Related]
5. Loss of Wave1 gene defines a subtype of lethal prostate cancer.
Sowalsky AG; Sager R; Schaefer RJ; Bratslavsky G; Pandolfi PP; Balk SP; Kotula L
Oncotarget; 2015 May; 6(14):12383-91. PubMed ID: 25906751
[TBL] [Abstract][Full Text] [Related]
6. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
7. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
8. [Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].
Campedel L; Kossaï M; Blanc-Durand P; Rouprêt M; Seisen T; Compérat E; Spano JP; Malouf G
Bull Cancer; 2017 Sep; 104(9):789-799. PubMed ID: 28673439
[TBL] [Abstract][Full Text] [Related]
9. Genomic Aberrations Drive Clonal Evolution of Neuroendocrine Tumors.
Kaushik AK; Sreekumar A
Trends Endocrinol Metab; 2016 May; 27(5):242-244. PubMed ID: 27037211
[TBL] [Abstract][Full Text] [Related]
10. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
11. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
12. [Molecular biology of castration-resistant prostate cancer].
Doucet L; Terrisse S; Gauthier H; Pouessel D; Le Maignan C; Teixeira L; Culine S
Bull Cancer; 2015 Jun; 102(6):497-500. PubMed ID: 26028493
[TBL] [Abstract][Full Text] [Related]
13. A Complete Metabolic Response of Metastatic Castration-resistant Neuroendocrine Carcinoma of the Prostate After Treatment with RRx-001 and Reintroduced Platinum Doublets.
Brzezniak C; Oronsky B; Aggarwal R
Eur Urol; 2018 Feb; 73(2):306-307. PubMed ID: 28943185
[No Abstract] [Full Text] [Related]
14. The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.
Hovelson DH; Tomlins SA
Cancer J; 2016; 22(5):357-361. PubMed ID: 27749331
[TBL] [Abstract][Full Text] [Related]
15. [Updated treatment of castration-resistant prostate cancer].
Xu S; Zhang ZY
Zhonghua Nan Ke Xue; 2014 Dec; 20(12):1136-40. PubMed ID: 25597184
[TBL] [Abstract][Full Text] [Related]
16. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
17. [Current status of castration-resistant prostate cancer translational research].
Maeno A; Habuchi T
Nihon Rinsho; 2016 Jan; 74(1):40-4. PubMed ID: 26793877
[TBL] [Abstract][Full Text] [Related]
18. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.
Munari E; Cima L; Massari F; Bertoldo F; Porcaro AB; Caliò A; Riva G; Ciocchetta E; Ciccarese C; Modena A; Iacovelli R; Sava T; Eccher A; Ghimenton C; Tortora G; Artibani W; Novella G; Bogina G; Zamboni G; Sanguedolce F; D'Amuri A; Martignoni G; Brunelli M
Int J Biol Markers; 2017 May; 32(2):e243-e247. PubMed ID: 28085175
[TBL] [Abstract][Full Text] [Related]
20. Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer.
Mittal K; Donthamsetty S; Kaur R; Yang C; Gupta MV; Reid MD; Choi DH; Rida PCG; Aneja R
Br J Cancer; 2017 Apr; 116(9):1186-1194. PubMed ID: 28334734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
